Results 211 to 218 of about 983,540 (218)

Letter to the Editor Regarding: "Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults". [PDF]

Infect Dis Ther
Daungsupawong H, Wiwanitkit V.
europepmc   +1 more source

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy. [PDF]

Front Immunol
Gangaev A, van Sleen Y, Brandhorst N, Hoefakker K, Prajapati B, Singh A, Boerma A, van der Heiden M, Oosting SF, van der Veldt AAM, Hiltermann TJN, GeurtsvanKessel CH, Dingemans AC, Smit EF, de Vries EGE, Haanen JBAG, Kvistborg P, van Baarle D.   +17 more
europepmc   +1 more source

Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data.

JMIR Res Protoc
Burhan E, Azzumar F, Sinuraya FAG, Rakasiwi MID, Akbar I, Mubarak F, Rengganis AT, Rachmadi RA, Afidjati H.   +8 more
europepmc   +1 more source

Correction: BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.

Clin J Am Soc Nephrol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study.

Lancet. Infectious Diseases (Print)
BACKGROUND Little epidemiological evidence exists on the protective effects of the JN.1-adapted mRNA vaccines against COVD-19 hospitalisation and death.
C. H. Hansen, R. Lassaunière, Morten Rasmussen, I. R. Moustsen-Helms, P. Valentiner-Branth   +4 more
semanticscholar   +1 more source